Like a ROCK: Sanofi takes out Kadmon for $1.9B, gains transplant drug

Kadmon’s decade-long commitment to developing ROCK inhibitors has culminated in a $1.9 billion takeout by Sanofi, less than two months after the biotech’s first drug approval.

The deal gives Sanofi (Euronext:SAN; NASDAQ:SNY) Rezurock belumosudil, a ROCK2 inhibitor that gained FDA’s approval on July 16 for chronic graft-versus-host disease (GvHD). Kadmon Holdings Inc. (NASDAQ:KDMN) launched Rezurock last month, and has yet to report initial sales...